Resmetirom 80 mg, 30 Tablets
€170,00
Resmetirom 80 mg, 30 Tablets
Selective thyroid hormone receptor beta (THR-β) agonist indicated for the treatment of adults with non-cirrhotic MASH/NASH and liver fibrosis stages F2–F3. Resmetirom helps reduce liver fat accumulation, improves lipid metabolism, and may contribute to reducing inflammation and fibrosis progression.
Each pack contains 30 tablets of 80 mg. Intended for once-daily administration as prescribed by a healthcare professional, alongside diet and regular physical activity.
Description
“`html
Resmetirom 80 mg
30 tablets
A selective thyroid hormone receptor beta agonist, THR-β, indicated for the treatment of adult patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and stage F2–F3 liver fibrosis.
Dosage form
Tablets
Strength
80 mg
Pack size
30 tablets
One pack provides
30 days*
*When prescribed as one tablet once daily.
What is Resmetirom?
Resmetirom is a medicinal product used for the treatment of metabolic dysfunction-associated steatohepatitis,
MASH, previously known as nonalcoholic steatohepatitis,
NASH.
The medicine belongs to a class of selective thyroid hormone receptor beta agonists,
THR-β. These receptors are found predominantly in the liver and are involved in the regulation of lipid metabolism.
Activation of THR-β helps increase fatty acid metabolism, reduce fat accumulation in the liver, and improve processes associated with inflammation and fibrosis of liver tissue.
How does Resmetirom work?
| Mechanism | Potential therapeutic effect |
|---|---|
| THR-β activation | Activates thyroid hormone receptor beta primarily in liver cells. |
| Lipid metabolism | Enhances the breakdown and oxidation of fatty acids. |
| Liver fat | Helps reduce excessive fat accumulation in liver tissue. |
| Inflammation | Reduction of liver fat may help decrease inflammatory activity. |
| Fibrosis | Treatment may help improve fibrosis without worsening MASH activity. |
Indications for use
Resmetirom is used together with diet and physical activity for the treatment of:
Adult patients with noncirrhotic MASH/NASH
The condition must be accompanied by moderate to advanced liver fibrosis corresponding to stages
F2–F3.
The decision to start treatment is made by a physician based on the clinical presentation, laboratory findings, and assessment of liver condition.
Dosage and administration
| Patient body weight | Recommended daily dose | Pack suitability |
|---|---|---|
| Less than 100 kg | 80 mg once daily | Resmetirom 80 mg, 30 tablets |
| 100 kg or more | Usually 100 mg once daily | A different strength is required as prescribed by a physician |
Important information
Resmetirom is not a substitute for diet, weight management, or physical activity. It is used as part of a comprehensive treatment plan under medical supervision.
“`html
What should I do if I miss a dose?
Take the missed dose as soon as you remember.
If it is almost time for your next dose, skip the missed dose and continue treatment according to your usual schedule.
Possible adverse reactions
| Category | Possible manifestations |
|---|---|
| Most common reactions | Diarrhea, nausea, itching, vomiting, constipation, abdominal pain and dizziness. |
| Liver function abnormalities | Elevated liver enzymes may occur. Rare cases of drug-induced liver injury have been reported. |
| Gallbladder disorders | Gallstones, cholecystitis and other biliary complications may occur. |
Seek immediate medical attention
Stop taking the medicine and seek urgent medical attention if any of the following occur:
- yellowing of the skin or eyes;
- dark urine;
- severe weakness or unusual fatigue;
- persistent nausea or vomiting;
- severe pain in the upper right abdomen;
- fever or chills;
- rash, swelling of the face or lips, or difficulty breathing.
Contraindications and precautions
| Condition or category | Recommendation |
|---|---|
| Decompensated liver cirrhosis | Use should be avoided. |
| Moderate or severe hepatic impairment | Treatment should not be initiated without a physician’s decision. |
| Compensated cirrhosis | Safety and efficacy have not been adequately established. |
| Patients under 18 years of age | Safety and efficacy in pediatric patients have not been established. |
| Gallbladder disease | Medical supervision and monitoring are recommended. |
| Pregnancy and breastfeeding | Treatment should only be considered after a physician evaluates the benefits and risks. |
“`html
Drug Interactions
Inform your healthcare provider about all medicines you are taking before starting treatment.
| Drug or Drug Class | Recommendation |
|---|---|
| Strong CYP2C8 inhibitors (e.g. gemfibrozil) | Concomitant use is not recommended due to significant increase in Resmetirom exposure. |
| OATP1B1/OATP1B3 inhibitors (e.g. cyclosporine) | Co-administration is generally not recommended. |
| Statins | Dose adjustment and clinical monitoring may be required due to increased statin exposure. |
| CYP2C8 substrate medicines | Increased plasma concentrations may occur. Medical supervision is recommended. |
Storage Conditions
Temperature
Store below 30°C
Keep out of reach
Keep out of reach of children
Packaging
Store in the original package
Medical Disclaimer
This information is intended for educational purposes only and should not replace consultation with a qualified healthcare professional. Do not use this information for self-diagnosis, self-treatment, dose adjustment, or discontinuation of prescribed therapy without medical advice.
Pharmaceutical Classification
Therapeutic area: Hepatology
Pharmacological class: Selective thyroid hormone receptor beta (THR-β) agonist
Category: Pharmaceutical products / Liver disease treatment
Frequently Asked Questions about Resmetirom 80 mg
Answers to the most common questions regarding treatment with Resmetirom





Reviews
There are no reviews yet.